Vedang Murthy

Very pleased to share the results of the eternal question on the usefulness of Pelvic RT in High Risk Prostate cancer. Hope the debate will settle now. Thanks for the great support. doi.org/10.1200/JCO.20… @TataMemorial @ACTREC_TMC @docpriyamvada #JCO @ASCO_pubs @APCCC_Lugano

Thrilled and Grateful. Our review on metastasis-directed therapy in oligometastatic prostate cancer is now out in Seminars in Radiation Oncology. Thank you so much @VedangMurthy @piet_ost for your guidance and belief! Full text authors.elsevier.com/c/1lFrI3lXQoc1…

New review led by @DeepOnco of @royalmarsdenNHS outlines global trends and evolving diagnostics, treatment, and surveillance of #ProstateCancer. Read: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @PCaParker @AmarUKishan @VedangMurthy @nickva1 @alison_tree @APCCC_Lugano @ICR_London

One possible step to solve this issue could be integration of PSMA PET. We don’t know how many patients in these trials have been cN+ or cM+. Our own data suggests that cN+ for example is a bad prognostic factor: jamanetwork.com/journals/jaman… @VedangMurthy @nina_hegemann @jcpeeken

Delighted to share our comprehensive review on #ProstateCancer, now out in @CACancerJournal , the highest-impact STEM journal. Huge thanks to an amazing team ! @alison_tree @PCaParker @AmarUKishan @VedangMurthy @nickva1 @royalmarsdenNHS @ICR_London Link: doi.org/10.3322/caac.7…

This should be a lot of fun!

What a great summary on treatment of #Oligometastatic #ProstateCancer ! Congrats @VedangMurthy @drmaneesh_singh @piet_ost Good learning for every Resident and Senior Faculty! 💪🏻💪🏻

Thanks Mel. Yes it's turned out to be quite nice. @piet_ost is so impressed that he has promised to have it in all his presentations.... ... Regardless of the topic! 😀

Thanks so much @VedangMurthy for putting together the first ever #APCCC #SouthAsia and for including #SriLanka. It was great to meet so many colleagues from #SouthAsia #Prostatecancer #oncology @Vimukthini @YasiruMalinda @docpriyamvada

Finally Managed to gather a fantastic bunch of KOLs from India 🇮🇳 Bangladesh Sri Lanka and Nepal. Discussed the nuances of PCa Mx. Plenty of friendly banter and leg pulling. Official APCCC South Asia. Paper with similarities yet differences from @APCCC_Lugano coming soon.

I’d truly fall out of my chair if 1-5 Fx of SBRT were on average more toxic than surgery for early stage lung, especially with how advanced technology has become in recent years.

A lot to learn and adapt for sure . Some perspective, gains in Reduction in time toxicity for patients and resource optimization with simless adaptive , AI driven support for when , how with additional workflow of adaptive on demand and all this to translate into better outcome

Loading: Exercisumab, Cardiobrutinib, Circadekinib and Chronokizumab!! 😅

EXTEND showed us that MDT + ADT > ADT RADIOSA showed MDT + ADT > MDT. STORM / PEACE-V showed ENI + MDT + ADT > MDT + ADT All studies had some novel imaging defined mHSPC (STORM was 100% novel) Can we just accept that MDT (+/- elective RT) + ADT is better than either?!?

100% agree. Same with avoiding salvage RT after BCR and waiting for PET to be positive. Sensitivity far too low to rule out locoregional disease. Waiting until PET positive is effectively waiting for metastatic spread in many cases. Only positive trial of pelvic nodal RT in…